A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2020

ABSTRACT

Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma. Detailed Description Mesothelioma is an aggressive malignancy usually affecting the surfaces of body coelomic cavities. It most commonly originates from the pleura with a propensity to the lower parietal pleura and costo-diaphragmatic recess, and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Outcomes for most patients are invariably fatal, with median survival from presentation around 9-12 months in most series due to difficulties in achieving a complete microscopic surgical resection and tumour relative chemo-refractoriness. Whilst initially considered rare, due to the demand of asbestos of all varieties associated with industrialization following the Second World War, the background incidence of mesothelioma of 1/million has risen to 40/million in some countries. In the UK, where substantial asbestos exposure continued until the 1970s, the death rate is the highest in the world with a current epidemic of new cases, predicted to continue for another 5-10 years. Two main histological subtypes of mesothelioma are identified. The epitheliod subtype is the commonest, accounting for around 40% of cases, whilst the sarcomatoid subtype is observed in 20% of cases; the latter being typically aggressive and chemorefractory. Around 35% cases have features of both epitheliod and sarcomatoid subtypes and are termed biphasic subtype. For patients with pleural mesothelioma, in whom surgery is not considered appropriate, systemic chemotherapy (platinum combined with pemetrexed) remains the international standard of care. Cisplatin/pemetrexed is associated with a response rate of 41% and confers an OS advantage of 3 months over cisplatin alone, and is the only licensed systemic therapy for mesothelioma in Europe. Despite this, the median survival is 9-12 months from most series in unresectable cases. At relapse, after platinum-based chemotherapy, no anti-cancer systemic therapies are licensed. Whilst several small phase II studies and retrospective series have suggested potential efficacy for chemotherapy with agents including carboplatin/gemcitabine, or vinorelbine, none thus far have demonstrated efficacy benefit in a randomised study, with median PFS rates reported of about 3 months for both gemcitabine and vinorelbine. There is therefore a huge unmet need for effective therapy for patients with relapsed pleural mesothelioma. The largest trial ever performed of systemic therapy in relapsed pleural mesothelioma in 661 patients documented the natural outcome of this group of relapsed mesothelioma patients, reporting a median OS of 27.1 weeks (6 months) and median PFS for 6.1 weeks (1.5 months) for placebo. Programmed cell death-1 (PD-1) is a co-inhibitory molecule at the immunological synapse that acts as a major regulator of adaptive immunity, and is exploited by tumour cells to result in adaptive immune resistance (tolerance). This occurs when PD-1 binds to the ligands PD-L1 (B7H1) or PD-L2, which are expressed on many tumour types. High PD-L1 expression on tumours is associated with poorer outcomes. Mesothelioma has been shown to express PD-L1, with a small study identifying PDL1 expression in up to 40% of mesotheliomas. Moreover, immunologically-mediated inflammation is known to be a key driver for mesothelioma development via the Nalp3 imflammasome. Pembrolizumab (MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. There is a need to identify new ways for the systemic therapy of malignant mesothelioma and immune checkpoint inhibition is a promising way forward. Results from the proposed trial will contribute to overcoming tumour-specific immune suppression with immune checkpoint inhibition. More... »

URL

https://clinicaltrials.gov/show/NCT02991482

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma.\n\nDetailed Description\nMesothelioma is an aggressive malignancy usually affecting the surfaces of body coelomic cavities. It most commonly originates from the pleura with a propensity to the lower parietal pleura and costo-diaphragmatic recess, and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Outcomes for most patients are invariably fatal, with median survival from presentation around 9-12 months in most series due to difficulties in achieving a complete microscopic surgical resection and tumour relative chemo-refractoriness. Whilst initially considered rare, due to the demand of asbestos of all varieties associated with industrialization following the Second World War, the background incidence of mesothelioma of 1/million has risen to 40/million in some countries. In the UK, where substantial asbestos exposure continued until the 1970s, the death rate is the highest in the world with a current epidemic of new cases, predicted to continue for another 5-10 years. Two main histological subtypes of mesothelioma are identified. The epitheliod subtype is the commonest, accounting for around 40% of cases, whilst the sarcomatoid subtype is observed in 20% of cases; the latter being typically aggressive and chemorefractory. Around 35% cases have features of both epitheliod and sarcomatoid subtypes and are termed biphasic subtype. For patients with pleural mesothelioma, in whom surgery is not considered appropriate, systemic chemotherapy (platinum combined with pemetrexed) remains the international standard of care. Cisplatin/pemetrexed is associated with a response rate of 41% and confers an OS advantage of 3 months over cisplatin alone, and is the only licensed systemic therapy for mesothelioma in Europe. Despite this, the median survival is 9-12 months from most series in unresectable cases. At relapse, after platinum-based chemotherapy, no anti-cancer systemic therapies are licensed. Whilst several small phase II studies and retrospective series have suggested potential efficacy for chemotherapy with agents including carboplatin/gemcitabine, or vinorelbine, none thus far have demonstrated efficacy benefit in a randomised study, with median PFS rates reported of about 3 months for both gemcitabine and vinorelbine. There is therefore a huge unmet need for effective therapy for patients with relapsed pleural mesothelioma. The largest trial ever performed of systemic therapy in relapsed pleural mesothelioma in 661 patients documented the natural outcome of this group of relapsed mesothelioma patients, reporting a median OS of 27.1 weeks (6 months) and median PFS for 6.1 weeks (1.5 months) for placebo. Programmed cell death-1 (PD-1) is a co-inhibitory molecule at the immunological synapse that acts as a major regulator of adaptive immunity, and is exploited by tumour cells to result in adaptive immune resistance (tolerance). This occurs when PD-1 binds to the ligands PD-L1 (B7H1) or PD-L2, which are expressed on many tumour types. High PD-L1 expression on tumours is associated with poorer outcomes. Mesothelioma has been shown to express PD-L1, with a small study identifying PDL1 expression in up to 40% of mesotheliomas. Moreover, immunologically-mediated inflammation is known to be a key driver for mesothelioma development via the Nalp3 imflammasome. Pembrolizumab (MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. There is a need to identify new ways for the systemic therapy of malignant mesothelioma and immune checkpoint inhibition is a promising way forward. Results from the proposed trial will contribute to overcoming tumour-specific immune suppression with immune checkpoint inhibition.", 
    "endDate": "2020-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02991482", 
    "keywords": [
      "Phase III", 
      "standard chemotherapy", 
      "Malignant pleural mesothelioma", 
      "trial", 
      "standard treatment", 
      "Drug Therapy", 
      "patient", 
      "malignant mesothelioma", 
      "mesothelioma", 
      "aggressive malignancy", 
      "surface", 
      "cavity", 
      "pleura", 
      "propensity", 
      "recess", 
      "asbestos exposure", 
      "lag time", 
      "exposure", 
      "presentation", 
      "median survival", 
      "surgical resection", 
      "refractoriness", 
      "whilst", 
      "demand", 
      "asbestos", 
      "industry", 
      "World War", 
      "incidence", 
      "country", 
      "UK", 
      "mortality", 
      "world", 
      "histological subtype", 
      "subtypes", 
      "commonest", 
      "feature", 
      "General Surgery", 
      "systemic chemotherapy", 
      "platinum", 
      "care", 
      "response rate", 
      "advantage", 
      "cisplatin", 
      "systemic therapy", 
      "Europe", 
      "Recurrence", 
      "platinum-based chemotherapy", 
      "Phase II study", 
      "potential efficacy", 
      "agent", 
      "vinorelbine", 
      "efficacy", 
      "randomised study", 
      "Pf", 
      "unmet need", 
      "effective therapy", 
      "large trial", 
      "natural outcome", 
      "OS", 
      "placebo", 
      "cell death", 
      "PD-1", 
      "inhibitory molecule", 
      "Immunological Synapsis", 
      "major regulator", 
      "Adaptive Immunity", 
      "tumor cell", 
      "immune resistance", 
      "tolerance", 
      "PD-L1", 
      "PD", 
      "tumor type", 
      "L1 expression", 
      "Neoplasm", 
      "poor outcome", 
      "small study", 
      "expression", 
      "inflammation", 
      "key driver", 
      "humanized monoclonal antibody", 
      "mAbs", 
      "isotypes", 
      "ligand", 
      "checkpoint", 
      "promising way", 
      "immune suppression"
    ], 
    "name": "A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02991482"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00023.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.413357.7", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.5072.0", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452288.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412004.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418624.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.417079.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.417993.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413354.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.424926.f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.425213.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.490781.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.8515.9", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418701.b", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.418670.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.120073.7", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.411057.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.439813.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.476298.6", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6604879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004357258", 
          "https://doi.org/10.1038/sj.bjc.6604879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncponc0839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009101685", 
          "https://doi.org/10.1038/ncponc0839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01281-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023503843"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)70056-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042742657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)67025-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047203194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncponc1039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049158968", 
          "https://doi.org/10.1038/ncponc1039"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.11.136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203976"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02991482"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02991482'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02991482'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02991482'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02991482'


 

This table displays all metadata directly associated to this object as RDF triples.

166 TRIPLES      16 PREDICATES      126 URIs      95 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02991482 schema:about anzsrc-for:3103
2 anzsrc-for:3142
3 schema:description Trial comparing standard treatment (chemotherapy) with pembrolizumab treatment in patients with advanced pretreated malignant mesothelioma. Detailed Description Mesothelioma is an aggressive malignancy usually affecting the surfaces of body coelomic cavities. It most commonly originates from the pleura with a propensity to the lower parietal pleura and costo-diaphragmatic recess, and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Outcomes for most patients are invariably fatal, with median survival from presentation around 9-12 months in most series due to difficulties in achieving a complete microscopic surgical resection and tumour relative chemo-refractoriness. Whilst initially considered rare, due to the demand of asbestos of all varieties associated with industrialization following the Second World War, the background incidence of mesothelioma of 1/million has risen to 40/million in some countries. In the UK, where substantial asbestos exposure continued until the 1970s, the death rate is the highest in the world with a current epidemic of new cases, predicted to continue for another 5-10 years. Two main histological subtypes of mesothelioma are identified. The epitheliod subtype is the commonest, accounting for around 40% of cases, whilst the sarcomatoid subtype is observed in 20% of cases; the latter being typically aggressive and chemorefractory. Around 35% cases have features of both epitheliod and sarcomatoid subtypes and are termed biphasic subtype. For patients with pleural mesothelioma, in whom surgery is not considered appropriate, systemic chemotherapy (platinum combined with pemetrexed) remains the international standard of care. Cisplatin/pemetrexed is associated with a response rate of 41% and confers an OS advantage of 3 months over cisplatin alone, and is the only licensed systemic therapy for mesothelioma in Europe. Despite this, the median survival is 9-12 months from most series in unresectable cases. At relapse, after platinum-based chemotherapy, no anti-cancer systemic therapies are licensed. Whilst several small phase II studies and retrospective series have suggested potential efficacy for chemotherapy with agents including carboplatin/gemcitabine, or vinorelbine, none thus far have demonstrated efficacy benefit in a randomised study, with median PFS rates reported of about 3 months for both gemcitabine and vinorelbine. There is therefore a huge unmet need for effective therapy for patients with relapsed pleural mesothelioma. The largest trial ever performed of systemic therapy in relapsed pleural mesothelioma in 661 patients documented the natural outcome of this group of relapsed mesothelioma patients, reporting a median OS of 27.1 weeks (6 months) and median PFS for 6.1 weeks (1.5 months) for placebo. Programmed cell death-1 (PD-1) is a co-inhibitory molecule at the immunological synapse that acts as a major regulator of adaptive immunity, and is exploited by tumour cells to result in adaptive immune resistance (tolerance). This occurs when PD-1 binds to the ligands PD-L1 (B7H1) or PD-L2, which are expressed on many tumour types. High PD-L1 expression on tumours is associated with poorer outcomes. Mesothelioma has been shown to express PD-L1, with a small study identifying PDL1 expression in up to 40% of mesotheliomas. Moreover, immunologically-mediated inflammation is known to be a key driver for mesothelioma development via the Nalp3 imflammasome. Pembrolizumab (MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. There is a need to identify new ways for the systemic therapy of malignant mesothelioma and immune checkpoint inhibition is a promising way forward. Results from the proposed trial will contribute to overcoming tumour-specific immune suppression with immune checkpoint inhibition.
4 schema:endDate 2020-12-01T00:00:00Z
5 schema:keywords Adaptive Immunity
6 Drug Therapy
7 Europe
8 General Surgery
9 Immunological Synapsis
10 L1 expression
11 Malignant pleural mesothelioma
12 Neoplasm
13 OS
14 PD
15 PD-1
16 PD-L1
17 Pf
18 Phase II study
19 Phase III
20 Recurrence
21 UK
22 World War
23 advantage
24 agent
25 aggressive malignancy
26 asbestos
27 asbestos exposure
28 care
29 cavity
30 cell death
31 checkpoint
32 cisplatin
33 commonest
34 country
35 demand
36 effective therapy
37 efficacy
38 exposure
39 expression
40 feature
41 histological subtype
42 humanized monoclonal antibody
43 immune resistance
44 immune suppression
45 incidence
46 industry
47 inflammation
48 inhibitory molecule
49 isotypes
50 key driver
51 lag time
52 large trial
53 ligand
54 mAbs
55 major regulator
56 malignant mesothelioma
57 median survival
58 mesothelioma
59 mortality
60 natural outcome
61 patient
62 placebo
63 platinum
64 platinum-based chemotherapy
65 pleura
66 poor outcome
67 potential efficacy
68 presentation
69 promising way
70 propensity
71 randomised study
72 recess
73 refractoriness
74 response rate
75 small study
76 standard chemotherapy
77 standard treatment
78 subtypes
79 surface
80 surgical resection
81 systemic chemotherapy
82 systemic therapy
83 tolerance
84 trial
85 tumor cell
86 tumor type
87 unmet need
88 vinorelbine
89 whilst
90 world
91 schema:name A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
92 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02991482
93 schema:sdDatePublished 2019-03-07T15:27
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N3a76cae0f08b433cb09adb82585d3f5d
96 schema:sponsor https://www.grid.ac/institutes/grid.120073.7
97 https://www.grid.ac/institutes/grid.411057.6
98 https://www.grid.ac/institutes/grid.412004.3
99 https://www.grid.ac/institutes/grid.413354.4
100 https://www.grid.ac/institutes/grid.413357.7
101 https://www.grid.ac/institutes/grid.417079.c
102 https://www.grid.ac/institutes/grid.417993.1
103 https://www.grid.ac/institutes/grid.418624.d
104 https://www.grid.ac/institutes/grid.418670.c
105 https://www.grid.ac/institutes/grid.418701.b
106 https://www.grid.ac/institutes/grid.424926.f
107 https://www.grid.ac/institutes/grid.425213.3
108 https://www.grid.ac/institutes/grid.439813.4
109 https://www.grid.ac/institutes/grid.452288.1
110 https://www.grid.ac/institutes/grid.476298.6
111 https://www.grid.ac/institutes/grid.490781.3
112 https://www.grid.ac/institutes/grid.5072.0
113 https://www.grid.ac/institutes/grid.8515.9
114 schema:startDate 2017-09-01T00:00:00Z
115 schema:subjectOf sg:pub.10.1038/ncponc0839
116 sg:pub.10.1038/ncponc1039
117 sg:pub.10.1038/sj.bjc.6604879
118 https://doi.org/10.1016/s0140-6736(05)67025-0
119 https://doi.org/10.1016/s0140-6736(15)01281-7
120 https://doi.org/10.1016/s1470-2045(15)70056-2
121 https://doi.org/10.1200/jco.2003.11.136
122 schema:url https://clinicaltrials.gov/show/NCT02991482
123 sgo:license sg:explorer/license/
124 sgo:sdDataset clinical_trials
125 rdf:type schema:MedicalStudy
126 N3a76cae0f08b433cb09adb82585d3f5d schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
129 rdf:type schema:DefinedTerm
130 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
131 rdf:type schema:DefinedTerm
132 sg:pub.10.1038/ncponc0839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009101685
133 https://doi.org/10.1038/ncponc0839
134 rdf:type schema:CreativeWork
135 sg:pub.10.1038/ncponc1039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049158968
136 https://doi.org/10.1038/ncponc1039
137 rdf:type schema:CreativeWork
138 sg:pub.10.1038/sj.bjc.6604879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004357258
139 https://doi.org/10.1038/sj.bjc.6604879
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1016/s0140-6736(05)67025-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047203194
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/s0140-6736(15)01281-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023503843
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/s1470-2045(15)70056-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042742657
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1200/jco.2003.11.136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203976
148 rdf:type schema:CreativeWork
149 https://www.grid.ac/institutes/grid.120073.7 schema:Organization
150 https://www.grid.ac/institutes/grid.411057.6 schema:Organization
151 https://www.grid.ac/institutes/grid.412004.3 schema:Organization
152 https://www.grid.ac/institutes/grid.413354.4 schema:Organization
153 https://www.grid.ac/institutes/grid.413357.7 schema:Organization
154 https://www.grid.ac/institutes/grid.417079.c schema:Organization
155 https://www.grid.ac/institutes/grid.417993.1 schema:Organization
156 https://www.grid.ac/institutes/grid.418624.d schema:Organization
157 https://www.grid.ac/institutes/grid.418670.c schema:Organization
158 https://www.grid.ac/institutes/grid.418701.b schema:Organization
159 https://www.grid.ac/institutes/grid.424926.f schema:Organization
160 https://www.grid.ac/institutes/grid.425213.3 schema:Organization
161 https://www.grid.ac/institutes/grid.439813.4 schema:Organization
162 https://www.grid.ac/institutes/grid.452288.1 schema:Organization
163 https://www.grid.ac/institutes/grid.476298.6 schema:Organization
164 https://www.grid.ac/institutes/grid.490781.3 schema:Organization
165 https://www.grid.ac/institutes/grid.5072.0 schema:Organization
166 https://www.grid.ac/institutes/grid.8515.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...